Pfizer: CMA wrongly excluded comparators in excessive pricing decision

Pfizer: CMA wrongly excluded comparators in excessive pricing decision

Pfizer has urged the UK’s Competition Appeal Tribunal to overturn the national enforcer’s finding that it excessively priced a lifesaving anti-epilepsy medication, arguing the authority erred in law by refusing to assess comparative products.

Unlock unlimited access to all Global Competition Review content